Optimal Screening for Genetic Diseases
Screening for genetic diseases is performed in many regions and/or ethnic groups where there is a high prevalence of possibly malign genes. The propagation of such genes can be considered dynamic externality. Given that many of these diseases are untreatable and give rise to truly tragic outcomes they are a source for societal concern and the screening process should perhaps be regulated. The present paper incorporates a standard model of genetic propagation into an economic model of dynamic management. The paper derives cost benefit rules for optimal screening. The highly non-linear nature of genetic dynamics gives rise to perhaps surprising results which include discontinuous controls and threshold effects. One insight is that a screening program, if at all in place at all at some point in time, should screen all individuals.
|Date of creation:||02 Jun 2009|
|Contact details of provider:|| Postal: HERO / Institute of Health Management and Health Economics P.O. Box 1089 Blindern, N-0317 Oslo, Norway|
Phone: 2307 5309
Fax: 2307 5310
Web page: http://www.hero.uio.no/eng.html
More information through EDIRC
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Emons, Winand, 2007.
"Genetic Tests and Intertemporal Screening in Competitive Insurance Markets,"
CEPR Discussion Papers
6047, C.E.P.R. Discussion Papers.
- Emons Winand, 2009. "Genetic Tests and Inter-Temporal Screening in Competitive Insurance Markets," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 9(1), pages 1-19, July.
- Winand Emons, 2006. "Genetic Tests and Intertemporal Screening in Competitive Insurance Markets," Diskussionsschriften dp0605, Universitaet Bern, Departement Volkswirtschaft.
- Francis, Peter J., 1997. "Dynamic epidemiology and the market for vaccinations," Journal of Public Economics, Elsevier, vol. 63(3), pages 383-406, February.
- Lundborg, Petter & Stenberg, Anders, 2010. "Nature, nurture and socioeconomic policy--What can we learn from molecular genetics?," Economics & Human Biology, Elsevier, vol. 8(3), pages 320-330, December.
- Fernando Antoñanzas & R. Rodríguez-Ibeas & M. Hutter & R. Lorente & C. Juárez & M. Pinillos, 2012. "Genetic testing in the European Union: does economic evaluation matter?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 651-661, October.
- Doherty, Neil A. & Thistle, Paul D., 1996. "Adverse selection with endogenous information in insurance markets," Journal of Public Economics, Elsevier, vol. 63(1), pages 83-102, December.
- Wirl, Franz, 1991. "Economics of (oil) price politics: Penalizing price changes," Journal of Policy Modeling, Elsevier, vol. 13(4), pages 515-527.
- Hoel, Michael & Iversen, Tor & Nilssen, Tore & Vislie, Jon, 2006. "Genetic testing in competitive insurance markets with repulsion from chance: A welfare analysis," Journal of Health Economics, Elsevier, vol. 25(5), pages 847-860, September.
When requesting a correction, please mention this item's handle: RePEc:hhs:oslohe:2008_002. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Anbjørg Kolaas)
If references are entirely missing, you can add them using this form.